Understanding the Market | RemeGen's stock rises over 5% as revenue in the first three quarters increases by 40% year-on-year, with losses significantly narrowing

RemeGen rose over 5%, as of the time of writing, up 5.44%, reported at HKD 89.1, with a transaction volume of HKD 225 million. In terms of news, RemeGen announced its performance for the first three quarters of 2025, with operating revenue of approximately RMB 1.72 billion, a year-on-year increase of 42.27%; the net loss attributable to shareholders of the listed company was approximately RMB 551 million, a year-on-year narrowing of 48.6%. The company indicated that due to a significant increase in product sales revenue, along with the optimization of its R&D pipeline and a decrease in various R&D expenses, coupled with the licensing agreement with the U.S. company Vor Bio to grant a paid license for the independently owned intellectual property of TaiTasiPu, this led to a reduction in overseas clinical costs for TaiTasiPu, resulting in a significant decrease in losses for the year. Additionally, on a quarterly basis, the company's third-quarter operating revenue was RMB 622 million, a year-on-year increase of 33.13%; the loss attributable to shareholders was RMB 101 million